Get the Stockscreener App
21.43
3.71%
-0.135
Zenas Biopharma Inc stock is traded at $21.43, with a volume of 398.56K.
It is down -3.71% in the last 24 hours and down -3.26% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
See More
Previous Close:
$21.56
Open:
$21.68
24h Volume:
398.56K
Relative Volume:
0.52
Market Cap:
$1.29B
Revenue:
$10.00M
Net Income/Loss:
$-377.74M
P/E Ratio:
-2.5374
EPS:
-8.4436
Net Cash Flow:
$-172.35M
1W Performance:
+15.27%
1M Performance:
-3.26%
6M Performance:
-32.00%
1Y Performance:
+84.70%
1-Day Range:
$20.27
$22.15
1-Week Range:
$17.39
$22.15
52-Week Range:
$8.51
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
20.76 | 1.29B | 10.00M | -377.74M | -172.35M | -8.4436 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Zenas BioPharma (ZBIO) CEO and entities report 3,220,880 shares owned - Stock Titan
Zenas BioPharma rises as CEO continues insider purchases - MSN
A Look At Zenas BioPharma (ZBIO) Valuation After Obexelimab Trial Success And US$300 Million Fundraising - Sahm
ZBIO Stock Price, Quote & Chart | ZENAS BIOPHARMA INC (NASDAQ:ZBIO) - ChartMill
Zenas BioPharma (ZBIO) Price Target Increased by 21.59% to 40.22 - MSN
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026 (NASDAQ:ZBIO) - Seeking Alpha
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity - MarketBeat
Zenas BioPharma rises on CEO insider purchase (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma CEO Makes Bold Move With Major Personal Stock Buy - TipRanks
Zenas BioPharma CEO Moulder buys $1.07m in ZBIO shares By Investing.com - Investing.com Canada
Leon Moulder Jr Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas BioPharma CEO Moulder buys $1.07m in ZBIO shares - Investing.com UK
Zenas BioPharma (ZBIO) CEO-linked entities purchase 60,000 shares in open market - Stock Titan
Zenas BioPharma announces concurrent public offerings of convertible senior notes and common stock - MSN
Here’s Why Zenas BioPharma (ZBIO) Traded Lower in Q1 - Insider Monkey
Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Hold" by Analysts - MarketBeat
Is Zenas BioPharma (ZBIO) stock priced efficiently (Weakens) 2026-04-20Community Pattern Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Zenas Biopharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: Exploring a 93% Potential Upside Amidst Analyst Enthusiasm - DirectorsTalk Interviews
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 21.4% in March - MarketBeat
Zenas BioPharma (ZBIO) Stock Volume Deceleration (On the Radar) 2026-04-15Crowd Entry Signals - Cổng thông tin điện tử Tỉnh Sơn La
Zenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings Results - MarketBeat
ZBIO Options Volatility — NASDAQ:ZBIO - TradingView
ZBIO Options Chain — NASDAQ:ZBIO - TradingView
Breakout Zone: Will Zenas BioPharma Inc outperform during market ralliesWeekly Investment Recap & Consistent Growth Stock Picks - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Big Picture: Is Zenas BioPharma Inc attractive at current valuationTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
Returns Recap: Can Zenas BioPharma Inc be the next market leader2026 Macro Impact & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Trend Review: What is the target price for Zenas BioPharma Inc stock2026 Fed Impact & AI Enhanced Trading Signals - baoquankhu1.vn
Investor Mood: What are Zenas BioPharma Incs growth levers2026 EndofYear Setup & Expert Approved Trade Ideas - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Experienced Healthcare Investor Buys Shares Of Zenas Biopharma – Insider Weekends (NASDAQ:ZBIO) - Seeking Alpha
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Assessing Zenas BioPharma (ZBIO) Valuation After US$300 Million Equity And Convertible Notes Financing - Sahm
Zenas BioPharma's Key Milestones and Market Context: Holding Through the BLA (NASDAQ:ZBIO) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Zenas BioPharma Director Makes Bold New Move With Fresh Stock Purchase - TipRanks
Zenas BioPharma Director Increases Stake with $70K Stock Purchase - National Today
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $70,197 By Investing.com - Investing.com Canada
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $70,197 - Investing.com
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Director Buys 3,768 Shares of Stock - marketbeat.com
Leon Moulder boosts Zenas BioPharma (ZBIO) stake to 4.794% ownership - Stock Titan
Zenas BioPharma (ZBIO) director-affiliated funds purchase 3,768 shares - Stock Titan
Zenas BioPharma (NASDAQ:ZBIO) Trading Up 7.6% Following Insider Buying Activity - MarketBeat
Zenas Biopharma Inc Stock (ZBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Apr 28 '26 |
Buy |
18.02 |
25,000 |
450,500 |
1,751,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
18.63 |
3,768 |
70,198 |
426,736 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Buy |
20.00 |
150,000 |
3,000,000 |
2,359,025 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 31 '26 |
Buy |
19.31 |
34,000 |
656,540 |
1,726,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 30 '26 |
Buy |
18.23 |
20,000 |
364,600 |
1,692,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
20.00 |
75,000 |
1,500,000 |
422,968 |
| Lu Hongbo | Director |
Feb 11 '26 |
Buy |
22.50 |
25,985 |
584,662 |
347,968 |
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 02 '26 |
Buy |
17.96 |
57,000 |
1,023,720 |
423,155 |
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):